Evidence map›Paper›PMID 36369267›Full record

ArticleScientific reports2022

Optogenetic restoration of high sensitivity vision with bReaChES, a red-shifted channelrhodopsin.

Lay Khoon Too, Weiyong Shen, Dario A Protti, Atomu Sawatari, Dylan A Black, Catherine A Leamey, Jin Y Huang, So-Ra Lee, Ashish E Mathai, Leszek Lisowski and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Optogenetic Vision Restoration.Cold Spring Harbor perspectives in medicine · 2024
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Lay Khoon TooSave Sight Institute, The University of Sydney, Sydney Eye Hospital South Block, 8 Macquarie St, Sydney, NSW, 2000, Australia.
Weiyong ShenSave Sight Institute, The University of Sydney, Sydney Eye Hospital South Block, 8 Macquarie St, Sydney, NSW, 2000, Australia.
Dario A ProttiNeuroscience, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
Atomu SawatariNeuroscience, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
Dylan A BlackNeuroscience, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
Catherine A LeameyNeuroscience, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
Jin Y HuangEducation Innovation Theme, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
So-Ra LeeSave Sight Institute, The University of Sydney, Sydney Eye Hospital South Block, 8 Macquarie St, Sydney, NSW, 2000, Australia.
Ashish E MathaiSave Sight Institute, The University of Sydney, Sydney Eye Hospital South Block, 8 Macquarie St, Sydney, NSW, 2000, Australia.
Leszek LisowskiChildren's Medical Research Institute, The University of Sydney, Sydney, NSW, 2006, Australia.
John Y LinSchool of Medicine, College of Health and Medicine, University of Tasmania, Tasmania, 7000, Australia.
Mark C GilliesSave Sight Institute, The University of Sydney, Sydney Eye Hospital South Block, 8 Macquarie St, Sydney, NSW, 2000, Australia.
Matthew P SimunovicSave Sight Institute, The University of Sydney, Sydney Eye Hospital South Block, 8 Macquarie St, Sydney, NSW, 2000, Australia. matthew.simunovic@sydney.edu.au.
University of Sydney · AUSydney Hospital · AUUniversity of Tasmania · AUWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The common final pathway to blindness in many forms of retinal degeneration is the death of the light-sensitive primary retinal neurons. However, the normally light-insensitive second- and third-order neurons persist optogenetic gene therapy aims to restore sight by rendering such neurons light-sensitive. Here, we investigate whether bReaChES, a newly described high sensitivity Type I opsin with peak sensitivity to long-wavelength visible light, can restore vision in a murine model of severe early-onset retinal degeneration. Intravitreal injection of an adeno-associated viral vector carrying the sequence for bReaChES downstream of the calcium calmodulin kinase IIα promoter resulted in sustained retinal expression of bReaChES. Retinal ganglion cells (RGCs) expressing bReaChES generated action potentials at light levels consistent with bright indoor lighting (from 13.6 log photons cm

Indexed as

Retinal DegenerationAnimalsChannelrhodopsinsHumansMiceOptogeneticsRetinal Ganglion CellsRod OpsinsChannelrhodopsinsRod Opsins

Identifiers

PMID36369267
PMCPMC9652428
OpenAlexW4308920315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.